Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis
Metformin is the first-line antidiabetic medication, and face-to-face comparisons between immediate-release and extended-release are scarce. The current meta-analysis aimed to compare metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. We s...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
UbiJournal
2023
|
Online Access: | http://psasir.upm.edu.my/id/eprint/110304/1/110304.pdf http://psasir.upm.edu.my/id/eprint/110304/ https://www.ijlpr.com/index.php/journal/article/view/1722 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.upm.eprints.110304 |
---|---|
record_format |
eprints |
spelling |
my.upm.eprints.1103042024-10-07T03:39:18Z http://psasir.upm.edu.my/id/eprint/110304/ Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis Alshadfan, Hisham Alamri, Marai Mirghani, Hyder Aljohani, Samar Alanazi, Mansuor Altemani, Faisal Alqahtani, Majed Albalawi, Ahmad Humadi, Abdulaziz Abdullah, Muhammad Nazrul Hakim Metformin is the first-line antidiabetic medication, and face-to-face comparisons between immediate-release and extended-release are scarce. The current meta-analysis aimed to compare metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. We searched PubMed, Cochrane Library, and the first 100 articles in Google Scholar from inception until September 2022. Studies were eligible if they were randomized controlled trials and compared metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. The keywords used were metformin immediate-release, extended-release, glycated hemoglobin, HbA1c, high-density lipoproteins, low-density lipoproteins triglycerides, total cholesterol, adverse effects, and side effects. The retrieved data were exported to an Excel sheet detailing the authors' names, the country of origin of the study, the number of patients and control subjects, and the total number of events in the interventional and control groups. No significant statistical difference was found between metformin immediate-release and metformin extended-release regarding the reduction of HbA1c, overall adverse effects, low-density lipoproteins, and high-density lipoproteins; odd ratio, 0.08, 95 CI, -0.14-0.29; 1.34, 95 CI, 0.86-2.08; -0.03, 95 CI, -0.22-0.17; and -0.26, 95 CI, -1.32-0.80 respectively. Metformin immediate-released reduced total cholesterol better than the extended-release; odd ratio, -2.35, 95 CI, -2.57-2.12. However, a paradox was observed regarding triglycerides (increment on extended-release and reduction with extended-release); odd ratio, -0.36, 95 CI, -0.44-0.28. No significant differences were found between the two formulations except for a better triglyceride reduction and total cholesterol in the immediate-release arm. UbiJournal 2023-07 Article PeerReviewed text en cc_by_nc_nd_4 http://psasir.upm.edu.my/id/eprint/110304/1/110304.pdf Alshadfan, Hisham and Alamri, Marai and Mirghani, Hyder and Aljohani, Samar and Alanazi, Mansuor and Altemani, Faisal and Alqahtani, Majed and Albalawi, Ahmad and Humadi, Abdulaziz and Abdullah, Muhammad Nazrul Hakim (2023) Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis. International Journal of Life Science and Pharma Research, 13 (4). pp. 173-181. ISSN 2250-0480; eISSN: 2250-0480 https://www.ijlpr.com/index.php/journal/article/view/1722 10.22376/ijlpr.2023.13.4.l173-l181 |
institution |
Universiti Putra Malaysia |
building |
UPM Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Universiti Putra Malaysia |
content_source |
UPM Institutional Repository |
url_provider |
http://psasir.upm.edu.my/ |
language |
English |
description |
Metformin is the first-line antidiabetic medication, and face-to-face comparisons between immediate-release and extended-release are scarce. The current meta-analysis aimed to compare metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. We searched PubMed, Cochrane Library, and the first 100 articles in Google Scholar from inception until September 2022. Studies were eligible if they were randomized controlled trials and compared metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. The keywords used were metformin immediate-release, extended-release, glycated hemoglobin, HbA1c, high-density lipoproteins, low-density lipoproteins triglycerides, total cholesterol, adverse effects, and side effects. The retrieved data were exported to an Excel sheet detailing the authors' names, the country of origin of the study, the number of patients and control subjects, and the total number of events in the interventional and control groups. No significant statistical difference was found between metformin immediate-release and metformin extended-release regarding the reduction of HbA1c, overall adverse effects, low-density lipoproteins, and high-density lipoproteins; odd ratio, 0.08, 95 CI, -0.14-0.29; 1.34, 95 CI, 0.86-2.08; -0.03, 95 CI, -0.22-0.17; and -0.26, 95 CI, -1.32-0.80 respectively. Metformin immediate-released reduced total cholesterol better than the extended-release; odd ratio, -2.35, 95 CI, -2.57-2.12. However, a paradox was observed regarding triglycerides (increment on extended-release and reduction with extended-release); odd ratio, -0.36, 95 CI, -0.44-0.28. No significant differences were found between the two formulations except for a better triglyceride reduction and total cholesterol in the immediate-release arm. |
format |
Article |
author |
Alshadfan, Hisham Alamri, Marai Mirghani, Hyder Aljohani, Samar Alanazi, Mansuor Altemani, Faisal Alqahtani, Majed Albalawi, Ahmad Humadi, Abdulaziz Abdullah, Muhammad Nazrul Hakim |
spellingShingle |
Alshadfan, Hisham Alamri, Marai Mirghani, Hyder Aljohani, Samar Alanazi, Mansuor Altemani, Faisal Alqahtani, Majed Albalawi, Ahmad Humadi, Abdulaziz Abdullah, Muhammad Nazrul Hakim Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis |
author_facet |
Alshadfan, Hisham Alamri, Marai Mirghani, Hyder Aljohani, Samar Alanazi, Mansuor Altemani, Faisal Alqahtani, Majed Albalawi, Ahmad Humadi, Abdulaziz Abdullah, Muhammad Nazrul Hakim |
author_sort |
Alshadfan, Hisham |
title |
Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis |
title_short |
Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis |
title_full |
Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis |
title_fullStr |
Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis |
title_full_unstemmed |
Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis |
title_sort |
metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis |
publisher |
UbiJournal |
publishDate |
2023 |
url |
http://psasir.upm.edu.my/id/eprint/110304/1/110304.pdf http://psasir.upm.edu.my/id/eprint/110304/ https://www.ijlpr.com/index.php/journal/article/view/1722 |
_version_ |
1814054701374636032 |
score |
13.211869 |